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We have developed a recombinant adenovirus vaccine encoding dopachrome tautomerase (rHuAd5-hDCT) that
produces robust DCT-specific immunity, but only provides modest suppression of murine melanoma. In the current
study, an agonist antibody against 4-1BB was shown to enhance rHuAd5-hDCT efficacy and evoke tumor regression, but
most tumors ultimately relapsed. The vaccine triggered upregulation of the immune inhibitory PD-1 signaling pathway
and PD-1 blockade dramatically enhanced the rHuAd5-hDCT + anti-4-1BB strategy, resulting in complete regression of
growing tumors in . 70% of recipients. The impact of the combined anti-4-1BB/anti-PD-1 treatment did not manifest as
a dramatic enhancement in either the magnitude or functionality of DCT-specific tumor infiltrating lymphocytes relative
to either treatment alone. Rather, a synergistic enhancement in intratumoral cytokine expression was observed,
suggesting that the benefit of the combined therapy was a local event within the tumor. Global transcriptional analysis
revealed immunological changes within the tumor following the curative vaccination, which extended beyond the T cell
compartment. We identified an immune signature of 85 genes associated with clearance of murine melanoma that
correlated with improved survival outcome in two independent cohorts of human melanoma patients. Our data reinforce
the concept that successful vaccination must overcome local hurdles in the tumor microenvironment that are not
manifest within the periphery. Further, tumor rejection following vaccination involves more than simply T cells. Finally,
the association of our immune signature with positive survival outcome in human melanoma patients suggests that
similar vaccination strategies may be promising for melanoma treatment.
Introduction
T cells play a key role in immune surveillance and tumor
rejection. Although immune tolerance limits the availability of
tumor-reactive T cells, anti-tumor T-cell responses can be
generated using recombinant viral vaccines.
1,2 We have demon-
strated that vaccination with a recombinant human adenovirus
serotype 5 (rHuAd5) vector expressing the human dopachrome
tautomerase antigen (hDCT; vector: rHuAd5-hDCT) elicited
robust protection against the B16F10 murine melanoma in
prophylactic and neo-adjuvant settings.
3-6 The same vaccine,
however, only provided modest therapeutic benefit against
growing tumors.
6,7 Although the mechanisms that limit the
vaccine’s activity against growing tumors remain to be deter-
mined, we have observed that the DCT-specific T-cell response
evoked by immunizing naïve animals is of greater magnitude
than the DCT response achieved in tumor-bearing mice,
demonstrating that the tumor imposes a constraint on vaccine
immunogenicity.
7
T cells elaborate multiple effector functions that lead to tumor
destruction, a property termed polyfunctionality, including the
secretion of cytotoxic granules
8 and the production of IFNc and
TNFa.
9-12 In the presence of high antigen burden, such as the
case of the tumor bed, T cells become impaired and lose their
polyfunctionality.
13 We have observed this phenomenon in
B16F10 tumors, where the polyfunctionality of DCT-specific
tumor infiltrating lymphocytes (TIL) was markedly diminished
in comparison to peripheral T cells.
7 Strategies to reverse this
impairment would be expected to enhance the therapeutic effect
of cancer vaccines.
Maximizing the activity of cancer vaccines necessitates an
appreciation of the complex regulatory pathways that control the
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T-cell response. Following ligation of the antigen receptor, T-cell
activation and function is regulated by costimulatory receptors
of the TNFR and CD28 families.
14,15 Of particular interest to
our study is the TNFR family member, 4-1BB, that plays a key
role in T-cell proliferation,
16,17 effector function,
18 and memory
formation.
19 Agonist 4-1BB monoclonal antibodies, used alone
or with cancer vaccines, can improve T-cell immunity against
poorly immunogenic tumors.
17,20-22 Of equal interest is PD-1, a
CD28 family member that negatively regulates T cell function.
PD-1 plays a role in limiting immune pathology
23 and is
upregulated on T cells exposed to high antigen levels, such as
tumor infiltrating lymphocytes.
24,25 Antagonists of PD-1 signaling
can partially reverse T cell exhaustion and improve T-cell-
mediated control of tumor growth.
26-28
In this manuscript, we have employed immunomodulatory
antibodies to enhance the efficacy of rHuAd5-hDCT. Treatment
with a 4-1BB agonist following vaccination markedly increased
the frequency of DCT-specific CD8
+ T cells, but only produced
transient tumor regression. Blockade of PD-1 signaling also
enhanced vaccine efficacy but complete tumor regression was only
achieved when 4-1BB co-stimulation was combined with PD-1
blockade. Strikingly, the benefit of the combined immunomo-
dulatory antibodies did not manifest as a dramatic alteration in
T-cell polyfunctionality despite evidence of a synergistic enhance-
ment of immune activity within the tumor. In fact, global
transcriptional analysis of the tumor following curative vaccina-
tion revealed significant upregulation of a gene signature that
extended beyond T cells, indicating that successful tumor rejec-
tion following vaccination requires more than simply vaccine-
induced T cells.
Results
Increased 4-1BB signaling can improve immune attack result-
ing in enhanced rHuAd5-hDCT efficacy. We hypothesized that
the limited anti-tumor efficacy of rHuAd5-hDCT could be
improved by employing an agonist monoclonal antibody against
4-1BB (a4-1BB), based on reports that this agonist could enhance
genetic vaccines
20,21,29,30 and recover TIL function.
31 4-1BB
expression on CD8
+ T cells was found to peak 5d post-
immunization with rHuAd5 and administration of the agonist
mAb 5 d following rHuAd5 immunization could enhance the
frequency of antigen-specific CD8
+ T cells in tumor-free mice
(data not shown). Similar outcomes were observed with 100 mg–
500 mgo fa4-1BB (data not shown), therefore we employed a
dose of 200 mg delivered on day 5 post-immunization for these
experiments. Immunization of tumor-bearing mice with rHuAd5-
hDCT + a4-1BB elicited a DCT-specific CD8
+ T cell response
that was 8.7-fold greater than rHuAd5-hDCT alone in the
peripheral blood (Fig.1A) which was associated with transient
tumor regression (Fig.1B) and improved overall survival
(Fig.1C); however, most tumors ultimately relapsed. It is notable
that progressive autoimmune vitiligo was observed in mice that
experienced complete tumor regression (Fig.1D). Treatment
with a4-1BB in combination with an irrelevant vaccine, rHuAd5-
LCMV-GP, did not elicit DCT-specific CD8
+ T cells (Fig.1A)
and had no impact on tumor growth or survival relative to
untreated mice (Fig.1C and data not shown). To gain further
insight into the events within the tumor, we measured the
expression of the T-cell-associated cytokines, IFNc and TNFa,
within the treated tumors. Whole tumor RNA was prepared from
mice that were vaccinated with rHuAd5-hDCT +/− a4-1BB or
the control vaccine rHuAd5-LCMV-GP + a4-1BB and cytokine
expression was measured by qRT-PCR. Whereas cytokine
expression in the tumors from mice immunized with rHuAd5-
hDCT alone peaked 5–7d post-vaccination and subsequently
declined (Fig.1E, broken line), treatment of tumor-bearing mice
with the vaccine and a4-1BB significantly enhanced immune
attack within the tumor (Fig.1E). Interestingly, TNFa pro-
duction was increased to a higher level than IFNc. The elevation
in cytokine expression was not due to the a4-1BB alone since
tumors from mice treated with rHuAd5-LCMV-GP in combina-
tion with a4-1BB revealed no change in cytokine expression
compared with untreated tumors (Fig.1F). Expression of both
IFNc and TNFa persisted for a prolonged period when rHuAd5-
hDCT was combined with a4-1BB, but began to decline around
the same time point that the tumors relapsed.
Therapeutic vaccination with rHuAd5-hDCT promotes
upregulation of the PD-1 signaling pathway within treated
tumors. The immunosuppressive receptor PD-1 is often up-
regulated on CD8
+ T cells faced with a high antigen burden, as
in the case of the tumor microenvironment,
24,25 so PD-1
expression was measured on vaccine-induced CD8
+ T cells in
the peripheral blood (PBL) and within the tumor (TIL). While
PD-1 expression was largely absent on DCT-specific CD8
+ PBL
(Fig.2A, upper left panels, gray histograms), PD-1 was signifi-
cantly upregulated on DCT-specific CD8
+ TIL, irrespective
of treatment with a4-1BB (Fig.2A, upper right panels, gray
histograms, rHuAd5-hDCT CD8
+ TIL MFI = 879.5 +/− 74.8,
rHuAd5-hDCT + a4-1BB CD8
+ TIL MFI = 838.0 +/− 87.4).
PD-1 expression by CD8
+ TIL required cognate interaction with
tumor-associated antigen because LCMV-GP-specific CD8
+ PBL
and TIL, which do not recognize antigen in B16F10 tumors,
were both largely PD-1-negative, in the presence or absence
of a4-1BB (Fig.2A, lower panels, gray histograms, rHuAd5-
LCMV-GP CD8
+ TIL MFI = 202.7 +/− 47.6, rHuAd5-LCMV-
GP + a4-1BB CD8
+ TIL MFI = 238.8 +/− 41.7).
We also investigated expression of the PD-1 ligands, PD-L1
and PD-L2, in the tumor following immunization. Quantitative
RT-PCR revealed that expression of PD-L1 and PD-L2 was
significantly upregulated in the tumor following treatment with
rHuAd5-hDCT +/− 4-1BB, but not in tumors from mice
immunized with rHuAd5-LCMV GP +/− 4-1BB or left untreated
(Fig.2B), confirming the likelihood that PD-1 ligand/PD-1
interactions were limiting the anti-tumor function of tumor
infiltrating CD8
+ T cells.
PD-1 blockade acts synergistically with 4-1BB co-stimulation
to enhance immune attack within the tumor leading to complete
tumor regression. Our data indicated that blockade of the PD-1
signaling pathway would be required to obtain the full benefit of
the enhanced immunogenicity of the rHuAd5-hDCT + a4-1BB
combination. Therefore, we combined the vaccination protocol
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Figure1. Stimulation of 4-1BB
enhances the DCT-specific
immune response following
vaccination resulting in
transient tumor regression and
improved survival. (A) Tumor-
bearing mice were immunized
with rHuAd5-hDCT or rHuAd5-
LCMV-GP and treated 5 d later
with a4-1BB or Rat IgG. DCT-
specific CD8
+ PBL were quan-
tified 10 d post-vaccination
(n = 5–20). (B and C) Tumor-
bearing mice were immunized
with rHuAd5-hDCT and treated
with a4-1BB (n; n = 20) or Rat
IgG (%; n = 9). As controls,
mice were immunized with
rHuAd5-LCMV-GP + a4-1BB
(N; n = 8). (D) Example of
progressive disseminated
autoimmune vitiligo observed
in cured mice following
rHuAd5-hDCT + a4-1BB treat-
ment. (E) Expression of IFNc
and TNFa in tumors from mice
immunized with rHuAd5-hDCT
+ a4–1BB (n;n=4 –8) or
rHuAd5-hDCT (%; n=4).
(F) Expression of IFNc and
TNFa in tumors 9 d after
treatment with rHuAd5-hDCT
+ a4-1BB (n = 7–9),
rHuAd5-LCMV-GP + a4-1BB
(n = 4) or untreated (n = 4).
Tumor volumes were
calculated from a single
representative experiment
(n = 4–5) and survival data was
compiled from independent
experiments. Data presented
as mean +/− SEM.
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with an antagonist monoclonal antibody to block PD-1 signaling
(aPD-1), delivered every third day beginning 3d post vaccina-
tion. PD-1 blockade alone had no impact on the DCT-specific
T-cell response produced by rHuAd5-hDCT (Fig.3A), but the
blockade did promote transient tumor regression (Fig.3B),
confirming the utility of the antibody to reverse local immune
defects within the tumor. Strikingly, the combination of aPD-1
and a41-BB acted synergistically to enhance the efficacy of
rHuAd5-hDCT, leading to complete regression of most tumors
(Fig.3B) despite no enhancement in the magnitude of the
DCT-specific CD8
+ T-cell response (Fig.3A). This synergistic
benefit manifested as a durable cure in . 70% of the mice, who
remained tumor-free (Fig.3C,p, 0.0001 compared with all
other treatments); the cured mice subsequently developed
progressive autoimmune vitiligo (Fig.3D). Mice immunized
with rHuAd5-LCMV-GP + a4-1BB + aPD-1 displayed no
change in tumor growth (data not shown) or long-term survival
(Fig.3C, closed diamonds).
The therapeutic benefit of the combination therapy is not
reflected in either the magnitude or functionality of the DCT-
specific CD8
+ TIL. To understand the benefit of the mAb
combination, we investigated the DCT-specific CD8
+ TIL
following the various treatments. Strikingly, the combination
treatments did not result in a significant change in the number of
DCT-specific TIL compared with vaccination alone (Fig.4A),
suggesting that the observed differences in tumor growth were
not due to increased infiltration of tumor-reactive T cells. The
polyfunctionality of the DCT-specific CD8
+ PBL and TIL was
Figure2. PD-1 is upregulated on tumor-specific CD8
+ TIL following tumor infiltration in the context of elevated immunosuppressive PD-1 ligand
expression in the tumor. (A) PD-1 was measured on antigen-specific CD8
+ PBL and TIL (gray histograms) 10 d following immunization with rHuAd5-hDCT
+/− a4-1BB or rHuAd5-LCMV-GP +/− a4-1BB. Dashed lines correspond to controls without PD-1 staining. Data presented from a single representative
sample (n = 5–8). (B) Expression of PD-L1 and PD-L2 in tumors from mice left untreated (n = 4), treated rHuAd5-hDCT +/− a4-1BB (n = 4–8), or rHuAd5-
LCMV-GP + a4-1BB (n = 4). Data presented as mean +/− SEM.
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examined to determine whether 4-1BB co-stimulation and/or
PD-1 blockade reversed the previously described functional
defects manifest in DCT-specific TIL.
7 Similar to our previous
report,
7 the DCT-specific CD8
+ T cells in the PBL were capable
of producing multiple cytokines (IFNc and TNFa) and under-
going degranulation (measured by mobilization of CD107a)
Figure3. Vaccination combined with 4-1BB stimulation and PD-1 blockade results in complete tumor regression. (A) Tumor-bearing mice were
immunized with rHuAd5-hDCT or rHuAd5-LCMV-GP and treated with a4-1BB and/or aPD-1 as indicated. DCT-specific CD8
+ T cells were quantified in
peripheral blood 10 d post vaccination (n = 3–20). rHuAd5-hDCT +/− a4-1BB data reproduced from Figure1 for reference. (B and C) Tumor-bearing mice
were immunized with rHuAd5-hDCT + a4-1BB + aPD-1 (m; n = 10), rHuAd5-hDCT + aPD-1 (&; n = 10) or rHuAd5-LCMV-GP + a4-1BB + aPD-1 (X;n=5 )
and rHuAd5-LCMV-GP + aPD-1 (#) (n = 5) as controls. rHuAd5-hDCT +/− a4-1BB survival data reproduced from Figure1 for reference. (D) Example of
progressive disseminated autoimmune vitiligo observed in cured mice following rHuAd5-hDCT + a4-1BB + aPD-1 treatment. Tumor volumes were
calculated from a single representative experiment (n = 4–5) and survival data was compiled from independent experiments. Data presented as
mean +/− SEM.
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(Fig.4B), while the DCT-specific CD8
+ TIL were compromised
in their ability to produce TNFa and degranulate (Fig.4C).
We noted small, but significant, increases in TIL functionality
in groups receiving the PD-1 mAb, as measured by increased
frequencies of IFNc
+/TNFa
+ and IFNc
+/CD107a
+ CD8
+ TIL,
suggesting that PD-1 blockade can recover some functionality in
the vaccine-induced TIL. However, the change in polyfunction-
ality was not significantly different between mice who received
aPD-1 alone and those that received a4-1BB + aPD-1, indicating
that this modest enhancement in polyfunctionality could not
explain the dramatic therapeutic effect.
Intratumoral transcriptional analysis reveals synergistic
enhancement of local T cell activity upon inclusion of a4-
1BB/aPD-1 treatment. We previously observed that intratumoral
production of IFNc and TNFa correlated with therapeutic
outcome (Fig.1E), therefore, to determine whether the com-
bination therapy was associated with enhanced immune attack
within the tumor, whole tumor RNA was isolated at discrete time
intervals following treatment with rHuAd5-hDCT or rHuAd5-
hDCT in combination with a4-1BB and/or aPD-1. Whereas
treatment with rHuAd5-hDCT + a4-1BB or aPD-1 alone only
resulted in transient elevation of IFNc and TNFa expression
within the tumor relative to treatment with rHuAd5-hDCT alone
(Fig.4Di and ii and data not shown), the combination of a4-1BB
and aPD-1 produced a synergistic enhancement of cytokine
expression relative to treatment with the individual mAbs
(Fig.4Di and ii). Further, the cytokine expression produced by
the combination treatment continued to escalate until the tumors
were too small to successfully retrieve RNA (day14), while the
cytokine expression in the mice receiving single mAbs plateaued
and, ultimately, declined as the tumors relapsed. We also observed
a synergistic enhancement in the expression of the PD-1 ligands
PD-L1 and PD-L2, reinforcing the reciprocity between immune
attack and upregulation of immune suppressive pathways in the
tumor (Fig.4Diii and iv).
Gene expression profiling of treated tumors reveals molecular
differences between vaccine treatment groups. Our results thus
far demonstrated that the combination therapy produces com-
plete tumor regression and a profound immune attack within
the tumor (as measured by IFNc and TNFa production). Yet,
this enhanced intratumoral immunity was not associated with
a remarkable change in the DCT-specific CD8
+ TIL. To gain
further insight into the mechanisms underlying the synergistic
enhancements achieved through the combination treatment,
we evaluated global transcriptional differences among tumors
comprising each of the four treatment groups (rHuAd5-hDCT
+/− a4-1BB and/or aPD-1). RNA was isolated from whole
tumors 9d post-vaccination and gene expression analyses were
conducted using three biological replicates for each treatment
group (n = 12). To gain insight into the biological differences
between the treatment groups, we first identified the top 25
genes associated with each treatment using prediction analysis
of microarrays (PAM), and completed a Gene Ontology (GO)
analysis
32 (Fig.5A; TableS1). GO analysis (Table 1) revealed
that several immune related processes were enriched in rHuAd5-
hDCT + a4-1BB + aPD-1 treated tumors, whereas cell survival
programs such as the negative regulation of apoptosis or JNK
signaling were enriched in the rHuAd5-hDCT treated tumors.
Interestingly, this suggests that treatment with the rHuAd5-
hDCT vaccine alone did not induce strong immunity against the
tumor, but rather resulted in activation of tumor cell survival
processes. Conversely, inclusion of + a4-1BB + aPD-1 with the
vaccine was sufficient to induce tumor immunity and overcame
the activation of survival processes.
Taken together, these transcriptional analyses suggest that the
combination of rHuAd5-hDCT with + a4-1BB + aPD-1 not
only results in induction of strong anti-tumor immunity, but
also overcomes the activation of tumor cell survival processes
associated with rHuAd5-hDCT treatment alone.
Treatment-induced changes in gene expression are associated
with good clinical outcome in human melanoma patients. Our
data suggest that rHuAd5-hDCT + a4-1BB + aPD-1 treatment
elicited durable cures through complex immunological mechan-
isms which seem to involve both T cell-dependent and
independent processes. We hypothesized that these same pro-
cesses may be involved in the clinical course of human melanoma.
To this end, we identified differentially expressed genes between
rHuAd5-hDCT + a4-1BB +PD-1 treated tumors and all other
treatment groups (Fig.6A). We identified 94 differentially
expressed Illumina probes, representing 85 unique genes, which
we defined as the immune-index (Fig.6B and C; Table S2).
To determine whether the biological changes embodied in our
immune-index gene signature were consistent with observations
in human melanoma patients, we interrogated the gene expres-
sion profiles of 123 metastatic melanoma samples (GSE19234,
GSE22155) for which patient survival data was also available.
Briefly, GSE19234 comprised 39 Stage III and 5 Stage IV
metastatic melanomas, whereas GSE22155 comprised 79 Stage
IV metastatic melanomas. Clinical outcome data was available
for all 44 GSE19234 patients and 76 of 79 GSE22155 patients.
Within the GSE19234 (Fig.6D) cohort, patients with high
immune-index scores experienced superior overall survival relative
to those patients with lower immune index scores, and overall
survival between these two groups was statistically different
Figure4 (See opposite page). 4-1BB co-stimulation and PD-1 blockade following vaccination synergize to increase immune activity within the tumor,
despite no increase in the number of DCT-specific CD8
+ T cells and only limited improvements in T cell polyfunctionality. (A) Tumor-bearing mice were
immunized with rHuAd5-hDCT and treated with a4-1BB, a4-1BB + aPD1, aPD-1 alone, or were given no additional treatment. DCT-specific CD8
+ TIL were
quantified 10 d post-vaccination (n = 5 per treatment group). (B) Representative flow cytometric analysis of IFNc and TNFa production and CD107a
mobilization from DCT-specific CD8
+ PBL following rHuAd5hDCT + a4-1BB + aPD-1 treatment as described in (A). Values correspond to mean values
calculated from compiled data (n = 9–19). (C) Representative flow cytometric analysis of IFNc and TNFa production and CD107a mobilization by
DCT-specific CD8
+ TIL for all treatments described in (A) (n = 5 per treatment group). Values correspond to mean values calculated from compiled data.
Data presented as mean +/− SEM. (D) Expression of IFNc, TNFa, PD-L1, and PD-L2 in tumors from mice treated with rHuAd5-hDCT in combination with
a4-1BB (n), a4-1BB + aPD-1 (m), or aPD-1 (&)( n=4 –8). a4-1BB data reproduced from Figure1 for reference.
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(HR: 0.38, p = 0.018) (Fig.6E) We observed a similar
improvement in survival between immune-index high and
immune-index low patients within the GSE22155 cohort (HR:
0.59, p = 0.035) (Fig.6F and G). Overall, these observations
demonstrate that the unique intratumoral biological processes
induced by rHuAd5-hDCT + a4-1BB + aPD-1 treatment are
associated with improved survival in two independent cohorts of
human melanoma patients. Notably, these data suggest that
cancer immunotherapies that elicit similar changes within human
tumors may be beneficial in the treatment of melanoma patients.
Discussion
In the current study, we have addressed the limited efficacy of a
prototypic cancer vaccine, rHuAd5-hDCT, against growing
B16F10 melanomas. It has been suggested that the kinetics of
the immune response elicited by vaccination may be too slow to
Table 1. Gene ontology biological process analysis of treatment specific
genes
Gene Ontology – Biological Processes
AdhDCT + 4-1BB + PD-1 p
Positive regulation of immune response 2.6 E-7
Positive regulation of response to stimulus 1.2 E-6
Activation of immune response 1.9 E-6
Positive regulation of immune system process 2.0 E-6
Leukocyte mediated immunity 1.2 E-4
AdhDCT
Negative regulation of apoptosis 2.8 E-2
Negative regulation of programmed cell death 2.9 E-2
Negative regulation of cell death 2.9 E-2
Regulation of JNK cascade 4.9 E-2
Regulation of stress-activated protein kinase signaling pathway 5.0 E-2
AdhDCT + 4-1BB
Immune response 3.8 E-4
Regulation of actin filament polymerization 1.8 E-3
Regulation of actin polymerization of depolymerization 2.2 E-3
Regulation of actin filament length 2.3 E-3
Regulation of protein polymerization 2.8 E-3
AdhDCT + PD-1 (Negative association genes, no positives)
Immune response 1.6 E-4
Antigen processing and presentation of peptide antigen 7.6 E-4
Immunoglobulin mediated immune response 2.4 E-3
B-cell mediated immunity 2.6 E-3
Lymphocyte mediated immunity 3.5 E-3
Figure5. Identification of treatment specific probes. (A) PAM analysis
was used to identify the top 25 probes associated with (A) rHuAd5-hDCT
+ a4-1BB + aPD-1, (B) rHuAd5-hDCT, and (C) rHuAd5-hDCT + a4-1BB.
There were no probes which were specifically associated with the
rHuAd5-hDCT + aPD-1 treatment (D).
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significantly impact rapidly growing tumors like B16F10.
However, our findings suggest that the true hurdle is the limited
intratumoral immune activity elicited by the vaccine.
It is notable that under circumstances where we combined
a4-1BB and aPD-1, we measured a synergistic increase in the
production of IFNc and TNFa within the tumor compared with
treatment with either mAb on its own, despite no increase
in tumor-specific TIL numbers or remarkable change in TIL
polyfunctionality. This observation demonstrates that the true
measure of vaccine activity requires analysis of intratumoral events
and may not be apparent from ex vivo analysis of circulating
T cells or TIL. This issue is of primary importance for extending
vaccine strategies to humans as most studies rely upon sampling
peripheral blood due to limited access to tumor tissues. Indeed,
it is clear from this report and others
25,33 that T cells in the
peripheral blood do not accurately reflect the cells in the tumor.
Figure6. rHuAd5-hDCT + a4-1BB + aPD-1 treatment probes are associated with positive outcomes in human melanoma patients. (A) Summary of
treatment comparisons to identify probes associated with treatment induced B16F10 tumor regression. (B) Probes that were differentially expressedi n
all comparisons are highlighted with Venn diagrams. Ninety-four probes were consistently overexpressed in the rHuAd5-hDCT + a4-1BB + aPD-1
treatment group relative to other treatments, whereas 0 probes were consistently under-expressed in the rHuAd5-hDCT + a4-1BB + aPD-1 treatment
group relative to other treatments (Immune index). (C) Heatmap displaying expression levels of the 94 probes in each treatment group, (a) rHuAd5-hDCT
+ a4-1BB + aPD-1, (b) rHuAd5-hDCT, (c) rHuAd5-hDCT + a4-1BB, (d) rHuAd5-hDCT + aPD-1. (D–G) Kaplan-Meier survival curves for human patients with
metastatic melanoma, (D) overall survival for 44 patients comprising the GSE19234 data set, (E) overall survival for the GSE19234 patient cohort divided
into immune-index high and immune-index low groups (F) overall survival for 76 patients comprising the GSE22155 data set, (G) overall survival for the
GSE22155 patient cohort divided into immune-index high and immune-index low groups.
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Our report goes further to demonstrate that ex vivo analysis of
TIL may not provide an accurate measure of the events within
the tumor either. Transcriptional analysis, however, provides an
accurate and important measure of these events.
We have interpreted the expression of IFNc and TNFa as
evidence of T-cell activity; however, it is equally possible that
other cell types, such as NK cells and macrophages, also con-
tributed to the expression of these cytokines and, thus, the
synergistic increase in local expression following treatment with
combined a4-1BB and aPD-1 may be the result of activation of
infiltrating populations other than T cells. Indeed monocytes,
macrophages and NK cells can express both 4-1BB and PD-1
receptors,
34-36 supporting the possibility that the ultimate anti-
tumor effect is due to the combined actions of these mAbs on
T cells as well as non-T-cells. Further investigation is required to
fully understand these mechanisms. As a step toward the
elucidation of non-T-cell-dependent mechanisms, we examined
global transcriptional changes in tumors that regressed and did
not regress. Strikingly, the majority of the most highly over-
expressed genes in the tumors from mice treated with the curative
therapy were consistent with T-cell, macrophage/dendritic cell,
and NK-cell infiltration, supporting a potential role for these cells
in tumor clearance.
Using global transcriptional data, we defined a set of immune
genes associated with tumors that undergo complete regression
and applied this gene set to transcriptome data from metastatic
melanoma samples taken from two natural history cohorts.
Strikingly, our immune-index gene signature was found to be
predictive of improved survival in human melanoma patients. It
has previously been reported that tumors displaying an inflam-
matory phenotype are associated with improved prognosis in
human melanoma patients through the use of similar transcrip-
tional profiling approaches.
37-39 In the present study, we have
identified a unique immune signature generated through the
delivery of a pre-clinical immunotherapy in the context of a
growing tumor that promotes tumor clearance. The observation
that this immune signature is predictive of survival outcome in
two independent cohorts of melanoma patients suggests that
development of therapeutic interventions that produce similar
changes of immune status in human melanoma tumor is worthy
of further investigation. These data indicate that global trans-
criptional analysis is a useful tool to bridge the gap between
preclinical discoveries and clinical challenges in humans. Further,
this study supports the inclusion of transcriptional signatures
derived from efficacious pre-clinical immunotherapy models as
useful secondary clinical endpoints for cancer immunotherapy
trials.
Overall, our findings further highlight the limitations of cancer
vaccines and reinforce the concept that optimal delivery of cancer
vaccines will require maximizing vaccine immunogenicity and
suppressing negative regulators of T-cell function.
40 Our data
also indicate that ex vivo analyses of PBL and TIL should be
interpreted with caution since they do not accurately reflect the
true immunological events within the tumor. Lastly, global
analysis of vaccine treatment resulting in regression of murine
tumors has revealed that similar immune signatures within human
tumors are associated with good clinical outcome, further
emphasizing the importance of understanding immunological
changes within pre-clinical tumors as a means of improving the
treatment of human cancer.
Materials and Methods
Mice. Female C57BL/6 mice were purchased from Charles
River Breeding Laboratory. All of our investigations have been
approved by the McMaster Animal Research Ethics Board.
Recombinant adenoviruses. The E1,E3-deleted recombinant
human adenovirus serotype 5 (rHuAd5) vectors
41 used in this
study have been described previously.
5,42 rHuAd5-hDCT
expresses the full-length human dopachrome tautomerase
(DCT) gene. rHuAd5-LCMV-GP encodes the dominant CD8
+
and CD4
+ T cell epitopes of the lymphocytic choriomeningitis
virus glycoprotein.
Tumor challenge and immunization. Mice were challenged
intradermally with 10
5 B16F10 cells. 10
8 pfu of Ad vector was
prepared in 100 ml sterile PBS and injected in both rear thighs
(50 ml/thigh) 5d after tumor challenge. Tumor growth was
monitored daily and measured with calipers every other day.
Tumor volume was calculated as width  length  depth.
Isolation of tumor infiltrating lymphocytes. TIL were isolated
as previously described.
7 Briefly, tumors were digested in a
mixture of 0.5 mg/mL collagenase type I (Gibco), 0.2 mg/mL
DNase (Roche) and 0.02 mg/mL hyalorunidase (Sigma) pre-
pared in Hank’s Buffered Saline (10 ml/250 mg of tumor). The
digested material was passed successively through 70 mm and
40 mm nylon cell strainers and lymphocytes were purified using
either mouse CD90.2 or CD45.2 positive selection by magnetic
separation (EasySep, StemCell Technologies, Inc.).
Monoclonal antibodies. Anti-PD-1 (clone RMP1-14) was
purchased from BioXcell and administered 3 d following vac-
cination using a schedule of 250mg/mouse every 3d
43 for a
total of four injections. Anti-4-1BB was produced at McMaster
University from the 3H3 hybridoma (kindly provided by
Robert Mittler, Emory University) and administered to mice
5d after vaccination at a dose of 200mg/mouse. Total rat IgG
(Sigma) was used as control. All flow cytometry antibodies
(anti-CD16/CD32, anti-CD28, anti-CD4-PE-Cy7, anti-CD8a-
PerCP-Cy5.5, anti-PD-1-PE, anti-CD107a-FITC, anti-IFNc-
APC and anti-TNFa-FITC) were purchased from BD
Biosciences.
Intracellular cytokine staining (ICS). CD8
+ T-cell epitope
peptides (DCT180–188, hDCT342–351, hDCT363–371, LCMV-
GP31–43 and LCMV-GP34–41) were purchased from Biomer
Technologies, dissolved in DMSO and stored at -20°C. The ICS
method has been described previously.
6 Briefly, lymphocytes
were stimulated with either the DCT or LCMV-GP peptides
(1 mg/mL) for 5h at 37°C in the presence of 8mg/mL anti-CD28
and 5 mg/mL brefeldin A (BD PharMingen). The CD107a
mobilization assay was performed by adding anti-CD107a-FITC
at the beginning of the peptide stimulation as described.
7 Data
were acquired on a FACSCanto (BD Biosciences) and analyzed
using FlowJo software (TreeStar).
428 OncoImmunology Volume 1 Issue 4© 2012 Landes Bioscience.
Do not distribute.
RNA extraction from solid tumors and quantitative real-time
PCR. Tumors were excised, snap-frozen in liquid nitrogen and
stored at -80°C. Tumors were homogenized in Trizol (Invitrogen)
using a Polytron PT 1200C (Kinematica) and total RNA was
extracted according to the manufacturer’s specifications. RNA
samples were further purified using an RNeasy mini kit (Qiagen)
and treated with Ambion’s DNA-free kit. Reverse transcription
was performed with Superscript III First-Strand (Invitrogen)
according to the manufacturer’s instructions. Quantitative PCR
was performed on an ABI PRISM 7900HT Sequence Detection
System (Applied Biosystems) using Perfecta SYBR Green
SuperMix, ROX (Quanta Biosciences). Reaction efficiency was
determined for individual primer sets using a minimum of five
serial dilutions to ensure similar efficiency between target and
endogenous control reactions. Data were analyzed via the delta/
delta CT method using the Sequence Detector Software version
2.2 (Applied Biosystems). Primer sequences were as follows:
IFNc (FWD CTTGAAAGACAATCAGGCCATC; REV
CAGCAGCGACTCCTTTTCC), TNFa (FWD AAATAG
CTCCCAGAAAAGCAAG; REV CTGCCACAAGCAGGA
ATGAG), PD-L1 (FWD AACCCGTGAGTGGGAAGAG;
REV CCTGTTCTGTGGAGGATGTG) and PD-L2 (FWD
ATAGGCAAGGAGCCCAGAAC; REV AACCCGGACTTC
CCCTACAC). GAPDH (FWD AGGAGCGAGACCCCACTA
AC; REV GGTTCACACCCATCACAAAC) was used as an
endogenous control.
Illumina beadchip data. RNA from three independent B16F10
melanoma tumors was isolated (as described above) 9d post-
vaccination for each of the different treatment groups. (rHuAd-
hDCT, rHuAd-hDCT + a4-1BB, rHuAd-hDCT + a4-1BB +
aPD-1, rHuAd-hDCT + aPD-1) and prepared for profiling on
MouseRef-8_V2 beadchips, according to manufacturer’s protocol
(Illumina). Treatment specific genes were determined using PAM
analysis and the top 25 genes for each treatment group were used
to complete a gene ontology analysis.
32
Comparison with clinical melanoma samples. We calculated
all Illumina probes which were consistently differentially
expressed between the rHuAd-hDCT + a4-1BB + aPD-1 treated
tumors and all other treatment groups (rHuAd-hDCT, rHuAd-
hDCT + a4-1BB, rHuAd-hDCT + aPD-1). Genes were
considered differentially expressed if the fold-change was . 1.5
and the p-value , 0.05 in each comparison (Two-tailed, unpaired
Student’s t-test).
44 Gene expression profiles of 123 melanoma
tumors for which clinical outcome data was available were
downloaded from the Gene Expression Omnibus [GEO,
GSE22153 (n = 57, Illumina human-6 v2.0 expression
beadchips),
38 GSE22154 (n = 22, Illumina HumanHT-12 V3.0
expression beadchips),
38 and GSE19234 (n = 44, Affymetrix
HG-U133 Plus 2.0 arrays)].
37 All data sets were filtered such that
when multiple probes recognized the same gene transcripts, only
the probe with the highest mean intensity was used. For cross-
platform comparisons, genes were mapped by Unigene IDs to
either Affymetrix HG-U133 Plus 2.0 arrays, Illumina human-6
v2.0 expression beadchips, or Illumina HumanHT-12 V3.0
expression beadchips. Affymetrix array expression files were
created from raw .cel files that were normalized using Robust
Multi-Array Analysis (RMA).
45 Illumina expression files were
created using the IlluminaExpressionFileCreator module avail-
able on Gene Pattern (http://genepattern.broadinstitute.org/gp/
pages/index.jsf), similar to Illumina BeadStudio, from raw .IDAT
files. The expression values for each gene were transformed such
that the mean was 0 and the standard deviation was 1 within each
individual data set. An immune index was calculated for each
patient as follows:
iP
P
iN
N
x x i j
nn
 

ð1Þ
Where x is the transformed expression, n is the number of genes
that could be mapped between platforms, P is the set of probes
with higher expression in rHuAd-hDCT + a4-1BB + aPD-1
treated tumors, and N is the set of probes with lower expression
in rHuAd-hDCT + a4-1BB + aPD-1 treated tumors.
46 The
median immune index value was used as the cut-point between
high and low immune index values. Kaplan-Meier analysis was
used to compare survival characteristics between patients with
high and low immune indices.
Statistical analysis. Two-tailed, unpaired Student’s t-tests
were used to compare two treatment groups. One and two way
Analysis of Variances (ANOVA) were used for data analysis of
more than two groups and a Bonferroni post test was utilized
to determine significant differences between treatment groups.
Survival data was compared using a logrank test. Results were
generated using GraphPad Prism 4.0b software. Differences
between means were considered significant at p , 0.05: *p ,
0.05, **p , 0.01, ***p , 0.001. NS: not significant.
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